WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]
Cord Blood Market Research – Competitive Trends and Macro Landscape
To apply cord blood market research to business decisions, a thorough understanding of the marketplace is required. There are a number of emerging trends, perinatal tissue types, and cell expansion technologies that are affecting the marketplace, but to fully understand their impact, historical context must be introduced. The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. The mid-2000s were a growth period for the U.S. cord blood market, but that trend has since subsided and the market in now in a phase of maturation and consolidation. [Read more…]